UK Lab Secures Breakthrough in Bladder Cancer with Phase III Trial Success
AstraZeneca’s immunotherapy drug, tisotumab vedotin (brand name Jemperli), has met its primary endpoint in a Phase III trial for unresectable or metastatic urothelial carcinoma (advanced bladder cancer), marking a potential ... Read More